TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV, L3
Market cap: $34.8B (12/18/2025)
Price: $30.35
Teva Extends Maturity Date of Revolving Credit Agreement to 2028
Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
Earnings Release
Shareholder votes
News, Securities Holder Rights or Indentures, Description of Registrant's Securities, Legal Opinion
Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes
Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
Annual Report to Security Holders
Q3
Q1
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Specialized Disclosure Report
Free Writing Prospectus